4.8 (712) In stock
Recent advances in treating breast cancer are reaching back to the past to the first known biomarker, human epidermal growth factor, to determine its value in treating patients
MLO LABline Daily - Feb 24th, 2024
Benefits and Applications of Oncotype DX Breast Recurrence Score Testing among Breast Cancer Patients: Current Recommendations and Controversies.
Current advances in prognostic and diagnostic biomarkers for solid cancers: Detection techniques and future challenges - ScienceDirect
Treatment of HER2-Low, HR-Positive, and TNBC: A Focus on HER2-Targeted and TROP2–Targeted Therapy
Imaging of HER2 detected receptor expression positive breast cancer: from detection to interpretation, Egyptian Journal of Radiology and Nuclear Medicine
Oncology
PDF] Molecular Features and Survival Outcomes of the Intrinsic Subtypes Within HER2-Positive Breast Cancer
Differential response of HER2-positive breast cancer to anti-HER2 therapy based on HER2 protein expression level
HER2 expression evolution from HER2-negative primary breast cancer to
Quantitative measurement of HER2 expression to subclassify ERBB2 unamplified breast cancer - Laboratory Investigation
Hormone Receptor And her2 Status Changes Can Influence Prognosis
Unleashing the power of anti-HER2 therapies in metastatic colorectal cancer: paving the way for a brighter future - ESMO Gastrointestinal Oncology
